PCM
NKTR icon

Prelude Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Prelude Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,677
Closed -$456K – 1237
2025
Q1 		$456K Buy
44,677
+32,449
+265% +$424K 0.03% 537
2024
Q4 		$171K Buy
+12,228
New +$216K 0.01% 1026
2020
Q4 		– Sell
-100
Closed -$25K – 1751
2020
Q3 		$25K Sell
100
-439
-81% -$138K ﹤0.01% 1292
2020
Q2 		$187K Buy
+539
New +$168K 0.01% 754
2020
Q1 		– Sell
-967
Closed -$313K – 1838
2019
Q4 		$313K Buy
+967
New +$280K 0.01% 714
2018
Q4 		– Sell
-25
Closed -$23K – 2046
2018
Q3 		$23K Buy
+25
New +$21.3K ﹤0.01% 1287
2018
Q2 		– Sell
-162
Closed -$259K – 1853
2018
Q1 		$259K Buy
162
+156
+2,600% +$201K 0.02% 624
2017
Q4 		$6K Sell
6
-1,100
-99% -$651K ﹤0.01% 1254
2017
Q3 		$398K Sell
1,106
-1,940
-64% -$607K 0.04% 436
2017
Q2 		$893K Buy
3,046
+1,875
+160% +$542K 0.08% 229
2017
Q1 		$412K Buy
1,171
+146
+14% +$32.8K 0.04% 359
2016
Q4 		$189K Buy
+1,025
New +$208K 0.02% 603
2016
Q3 		– Sell
-737
Closed -$157K – 1739
2016
Q2 		$157K Sell
737
-141
-16% -$31.5K 0.02% 582
2016
Q1 		$181K Sell
878
-2,411
-73% -$463K 0.03% 589
2015
Q4 		$831K Buy
3,289
+1,380
+72% +$284K 0.13% 186
2015
Q3 		$314K Sell
1,909
-938
-33% -$166K 0.05% 416
2015
Q2 		$534K Buy
2,847
+1,066
+60% +$183K 0.07% 293
2015
Q1 		$294K Sell
1,781
-63
-3% -$12.9K 0.04% 509
2014
Q4 		$429K Buy
1,844
+43
+2% +$9.19K 0.06% 354
2014
Q3 		$326K Sell
1,801
-38
-2% -$7.27K 0.05% 533
2014
Q2 		$354K Sell
1,839
-1,528
-45% -$270K 0.05% 508
2014
Q1 		$612K Buy
3,367
+1,820
+118% +$360K 0.08% 323
2013
Q4 		$263K Hold
1,547
– – 0.04% 541
2013
Q3 		$242K Sell
1,547
-2,335
-60% -$432K 0.04% 480
2013
Q2 		$673K Buy
+3,882
New +$595K 0.14% 184

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's NKTR Position: Q2 2025 in Review

Prelude Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 44,677 shares — an estimated $456K sold.

Prelude Capital Management first reported a position in NKTR in Q2 2013 and held it in 25 quarters. The position peaked at $893K in Q2 2017. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Prelude Capital Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 44,677 Nektar Therapeutics shares in Q2 2025, an estimated $456K.
  • Prelude Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 25 quarters.
  • Prelude Capital Management's Nektar Therapeutics position peaked at $893K in Q2 2017.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.